GenScript Biotech Corporation, a world-leading biotech company offering comprehensive solutions in gene, peptide, protein, and antibody research, is pleased to announce the 3rd Annual Gene and Cell Engineering Virtual Summit on July 26, 2023. The event will kick off at 11:00 a.m. Eastern Daylight Time in collaboration with the prominent science networking site, Labroots.
The summit will host an array of eminent scientists and researchers from academia, pharma, and biotech. Participants will explore the rapidly evolving landscape of synthetic biology technologies and their potential to create innovative therapies. The forum seeks to showcase the most exciting advancements in gene and cell therapy research, focusing on how these developments revolutionize therapeutic approaches toward diverse human diseases.
GenScript has been committed to making research easy for scientists worldwide for over two decades. GenScript has cemented its place at the forefront of the gene and cell engineering sector through its extensive services, which include gene synthesis, mRNA synthesis, peptide synthesis, custom antibody generation, and protein engineering. The company’s strength lies in its strategic partnerships, licensing agreements for cutting-edge technologies, and collaborations with scientists conducting pioneering research.
Also Read: Scipher Medicine Signs Multi-Target Partnership with Ionis
The 3rd Annual Gene and Cell Engineering Virtual Summit will open with Dr. Dimitrios L. Wagner, Head of R&D, at the Berlin Center for Advanced Therapies (BeCAT) for his presentation titled “CD3ζ as a Novel Integration Site for Reprogramming Immune Cells with Chimeric Antigen Receptors”. Attendees are invited to join the live event to learn more.
The event’s agenda also features riveting presentations from leading experts, including:
- “Advancing Protein Stabilization Therapeutic Development and DUBTAC Drug Discovery through Gene and Cell Engineering” by Dr. Yongli Shan from Vicinitas Therapeutics. Dr. Shan will discuss how Vicinitas Therapeutics uses gene and cell engineering for stable expression of disease-related proteins and screening of small-molecule drugs that inhibit protein degradation. He will also explore how genetically engineered cell lines facilitate induced-proximity-based small-molecule drug discovery.
- “Characterization and Biodistribution of REGENXBIO NAV® Platform Capsids: Under-employed Gene Therapy Vector AAV7” by Dr. Samantha Yost, Senior Scientist at REGENXBIO. Dr. Yost will shed light on the importance of studying naturally occurring AAV capsids and discuss the advantages of a whole-body approach when describing the biodistribution of novel vectors.
- “Harnessing iNKT Cells for ‘Off-The-Shelf’ Cancer Therapy” by Dr. Lili Yang, Associate Professor at UCLA. Dr. Yang will discuss the generation of allogeneic HSC-iNKT cells in vitro, their ability to target tumor cells, their safety, and low immunogenicity based on preclinical study findings.
The summit promises to provide a dynamic forum for discussing ground-breaking innovations in gene and cell engineering and fostering collaborations between scientists globally.
SOURCE: PRWeb